Cross-source evidence timeline
Leuprolide research timeline
Follow 212 selected, directly cited source records from April 9, 1985 through August 6, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT07455903↗
PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 14, 2026Literature metadata
PubMed record PMID 39177865↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
PubMed record PMID 41824265↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Clinical trials
ClinicalTrials.gov record NCT05765500↗
PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT04484818↗
PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT06169124↗
PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 41712259↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41712259 at 2026-08-10T18:13:42.694Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Clinical trials
ClinicalTrials.gov record NCT06378866↗
PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 42003759↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42003759 at 2026-08-10T18:13:48.759Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 41931341↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41931341 at 2026-08-10T18:13:46.810Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-03. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Clinical trials
ClinicalTrials.gov record NCT05896293↗
PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT05498272↗
PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT02319837↗
PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Leuprolide DailyMed SPL version 10↗
DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT03070886↗
PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 8, 2026Clinical trials
ClinicalTrials.gov record NCT07158021↗
PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 8, 2026Clinical trials
ClinicalTrials.gov record NCT04423211↗
PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05669664↗
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT07650240↗
PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Literature metadata
Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.↗
PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 2026 · month precisionAdded to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT07027124↗
PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05605964↗
PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00329043↗
PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT06305598↗
PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04126070↗
PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00544830↗
PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04194554↗
PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02772588↗
PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02960022↗
PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT06734130↗
PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT06330805↗
PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00936390↗
PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05700903↗
PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01786265↗
PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05320406↗
PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03902951↗
PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04455750↗
PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04734730↗
PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT03809000↗
PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Leuprolide DailyMed SPL version 9↗
DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT00001481↗
PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05189457↗
PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02023463↗
PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Drugs@FDA application ANDA215826↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215826 with status AP dated 2025-11-13, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT06348264↗
PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03678025↗
PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03298087↗
PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02903368↗
PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Drugs@FDA application ANDA217437↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217437 with status AP dated 2025-06-09, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT02278185↗
PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Leuprolide DailyMed SPL version 7↗
DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2025-04-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT00687739↗
PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03944434↗
PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT02685397↗
PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03035032↗
PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02366494↗
PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Leuprolide DailyMed SPL version 6↗
DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Regulatory
Drugs@FDA application ANDA217957↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT02927392↗
PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01194271↗
PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2024-08657↗
The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Regulatory
Federal Register notice 2024-04218↗
The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT00099086↗
PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02543255↗
PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2023
Clinical trials
ClinicalTrials.gov record NCT00541047↗
PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT06106932↗
PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Safety
FDA enforcement report D-1178-2023↗
FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Clinical trials
ClinicalTrials.gov record NCT00002889↗
PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04897958↗
PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02058706↗
PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Leuprolide DailyMed SPL version 5↗
DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT00001259↗
PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2023-03364↗
The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT03043807↗
PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2022
Regulatory
Leuprolide DailyMed SPL version 4↗
DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Regulatory
Drugs@FDA application ANDA215336↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT02064036↗
PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02716974↗
PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04225221↗
PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02770391↗
PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Drugs@FDA application ANDA212963↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT02268175↗
PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2022-03248↗
The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT03085095↗
PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02122198↗
PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2021
Regulatory
Federal Register notice 2021-24431↗
The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.↗
Added to PeptideScanner August 21, 2026Regulatory
Federal Register notice 2021-18072↗
The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.↗
Added to PeptideScanner August 21, 2026Regulatory
Drugs@FDA application ANDA213829↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT00003653↗
PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01338987↗
PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT02064582↗
PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02059213↗
PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Drugs@FDA application NDA213150↗
The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT00002633↗
PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026
Source year
2019
Clinical trials
ClinicalTrials.gov record NCT02969590↗
PeptideScanner retained ClinicalTrials.gov record NCT02969590 at 2026-07-30T20:44:36.693Z. Its registry update date was 2019-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00254397↗
PeptideScanner retained ClinicalTrials.gov record NCT00254397 at 2026-07-30T20:44:36.700Z. Its registry update date was 2019-10-16, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00669162↗
PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2019-11243↗
The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT00455689↗
PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Regulatory
Drugs@FDA application NDA205054↗
The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT00223665↗
PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00002597↗
PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00004635↗
PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01120236↗
PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2018-02667↗
The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT01116401↗
PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT01762943↗
PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00589472↗
PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2017-12908↗
The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT01023061↗
PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00225420↗
PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01431391↗
PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT02107391↗
PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00170157↗
PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00380406↗
PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2016
Clinical trials
ClinicalTrials.gov record NCT00928434↗
PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01750398↗
PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01076335↗
PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00943956↗
PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00903162↗
PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00454571↗
PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT00500110↗
PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00004426↗
PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00004436↗
PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00004438↗
PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00631527↗
PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2014
Regulatory
Federal Register notice 2014-23961↗
The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Regulatory
Federal Register notice 2014-19713↗
The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT01669291↗
PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01088529↗
PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01160328↗
PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Safety
FDA enforcement report D-1287-2014↗
FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Safety
FDA enforcement report D-1288-2014↗
FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Safety
FDA enforcement report D-1289-2014↗
FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Safety
FDA enforcement report D-1290-2014↗
FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Safety
FDA enforcement report D-1291-2014↗
FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Regulatory
Federal Register notice 2014-07330↗
The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT00003124↗
PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2013
Literature metadata
Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).↗
PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 1989 · month precisionAdded to PeptideScanner August 16, 2026Literature metadata
Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.↗
PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 2004 · month precisionAdded to PeptideScanner August 14, 2026Literature metadata
The role of leuprolide acetate therapy in triggering auto-immune thyroiditis.↗
PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2005 · month precisionAdded to PeptideScanner August 14, 2026Literature metadata
LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure.↗
PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 29, 2005 · day precisionAdded to PeptideScanner August 14, 2026Literature metadata
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?↗
PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 2005 · month precisionAdded to PeptideScanner August 14, 2026Literature metadata
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.↗
PubMed lists PMID 10321505 in Cancer chemotherapy and pharmacology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 1999 · year precisionAdded to PeptideScanner August 13, 2026Literature metadata
Managing advanced prostate cancer with Viadur (leuprolide acetate implant).↗
PubMed lists PMID 11998504 in Urologic nursing as Journal Article, Review, with publication-date metadata of 2001-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 2001 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
In vitro transdermal iontophoretic delivery of leuprolide under constant current application.↗
PubMed lists PMID 15245886 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, with publication-date metadata of 2004-07-23 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 23, 2004 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Leuprolide acetate treatment and myoma arterial size.↗
PubMed lists PMID 7651647 in Obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 1995 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis].↗
PubMed lists PMID 7936386 in Minerva ginecologica as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 1994 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Advanced endometriosis treatment with leuprolide acetate].↗
PubMed lists PMID 7991863 in Revista chilena de obstetricia y ginecologia as Case Reports, English Abstract, Journal Article, with publication-date metadata of 1993 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 1993 · year precisionAdded to PeptideScanner August 13, 2026Literature metadata
Leuprolide acetate for exhibitionism in Huntington's disease.↗
PubMed lists PMID 8041380 in Movement disorders : official journal of the Movement Disorder Society as Case Reports, Journal Article, with publication-date metadata of 1994-05 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 1994 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.↗
PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 1994 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma].↗
PubMed lists PMID 8065589 in Minerva ginecologica as English Abstract, Journal Article, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 1994 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol].↗
PubMed lists PMID 8065590 in Minerva ginecologica as Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 1994 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot.↗
PubMed lists PMID 8348161 in International journal of fertility and menopausal studies as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1993 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 1993 May-Jun · source-text precisionAdded to PeptideScanner August 13, 2026Literature metadata
Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.↗
PubMed lists PMID 8530573 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1995-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 1995 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
A phase II study of leuprolide in advanced/recurrent endometrial cancer.↗
PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 1997 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?↗
PubMed lists PMID 9146615 in The Journal of urology as Journal Article, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 1997 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?↗
PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 1997 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Leuprolide in the treatment of endometrial cancer.↗
PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 1997 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 1407643↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1407643 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1533022↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1533022 at 2026-07-30T21:56:46.935Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1621201↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1621201 at 2026-07-30T21:56:46.937Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-11. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1666142↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1666142 at 2026-07-30T21:56:47.772Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1748007↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1748007 at 2026-07-30T21:56:47.777Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1835275↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1835275 at 2026-07-30T21:56:47.778Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1941784↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1941784 at 2026-07-30T21:56:47.780Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1981209↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1981209 at 2026-07-30T21:56:47.782Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2106145↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2106145 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-01-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2115128↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2115128 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2119048↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2119048 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-08-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2120646↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2120646 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2410765↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2410765 at 2026-07-30T21:56:47.801Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1985-08-16. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 2474565↗
PeptideScanner retained PubMed bibliographic metadata for PMID 2474565 at 2026-07-30T21:56:47.803Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1989-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 1349596↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1349596 at 2026-07-30T21:56:46.926Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-03-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 1407904↗
PeptideScanner retained PubMed bibliographic metadata for PMID 1407904 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Clinical trials
ClinicalTrials.gov record NCT00002580↗
PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00002582↗
PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00429494↗
PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00003394↗
PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 23594627↗
PeptideScanner retained PubMed bibliographic metadata for PMID 23594627 at 2026-07-30T21:57:01.413Z. PubMed recorded a metadata revision date of 2013-04-18 and an Entrez history date of 2013-04-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 23078121↗
PeptideScanner retained PubMed bibliographic metadata for PMID 23078121 at 2026-07-30T21:57:01.393Z. PubMed recorded a metadata revision date of 2013-01-16 and an Entrez history date of 2012-10-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026
Source year
2012
Clinical trials
ClinicalTrials.gov record NCT00653757↗
PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00805935↗
PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2012-1433↗
The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.↗
Added to PeptideScanner August 21, 2026
Source year
2011
Regulatory
Federal Register notice 2011-14164↗
The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026
Source year
2010
Clinical trials
ClinicalTrials.gov record NCT00002881↗
PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2009
Clinical trials
ClinicalTrials.gov record NCT00063310↗
PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice E9-13272↗
The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Regulatory
Drugs@FDA application ANDA078885↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2006
Clinical trials
ClinicalTrials.gov record NCT00349258↗
PeptideScanner retained ClinicalTrials.gov record NCT00349258 at 2026-07-30T22:49:18.182Z. Its registry update date was 2006-07-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 16727932↗
PeptideScanner retained PubMed bibliographic metadata for PMID 16727932 at 2026-07-30T22:50:21.669Z. PubMed recorded a metadata revision date of 2006-05-26 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026
Source year
2005
Regulatory
Federal Register notice 05-20301↗
The Federal Register published notice 05-20301, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Regulatory
Federal Register notice 05-20302↗
The Federal Register published notice 05-20302, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT00004311↗
PeptideScanner retained ClinicalTrials.gov record NCT00004311 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00004344↗
PeptideScanner retained ClinicalTrials.gov record NCT00004344 at 2026-07-30T22:50:58.186Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT00004771↗
PeptideScanner retained ClinicalTrials.gov record NCT00004771 at 2026-07-30T22:50:58.183Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
Added to PeptideScanner August 13, 2026
Source year
2004
Regulatory
Drugs@FDA application NDA021731↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021731 with status AP dated 2004-12-14, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2003
Regulatory
Drugs@FDA application NDA021488↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021488 with status AP dated 2003-02-13, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2002
Regulatory
Drugs@FDA application NDA021379↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021379 with status AP dated 2002-07-24, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application NDA021343↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021343 with status AP dated 2002-01-23, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2001
Regulatory
Drugs@FDA application ANDA075721↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 075721 with status AP dated 2001-11-29, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2000
Regulatory
Drugs@FDA application ANDA075471↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 075471 with status AP dated 2000-10-25, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application NDA021088↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021088 with status AP dated 2000-03-03, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1998
Regulatory
Drugs@FDA application ANDA074728↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 074728 with status AP dated 1998-08-04, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Federal Register notice 98-13045↗
The Federal Register published notice 98-13045, attributed to FDA and its parent HHS department, on 1998-05-18. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.↗
Added to PeptideScanner August 21, 2026
Source year
1997
Regulatory
Drugs@FDA application NDA020708↗
The official Drugs@FDA dataset lists original submission 1 for NDA 020708 with status AP dated 1997-03-07, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1995
Regulatory
Drugs@FDA application NDA020517↗
The official Drugs@FDA dataset lists original submission 1 for NDA 020517 with status AP dated 1995-12-22, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application NDA019943↗
The official Drugs@FDA dataset lists original submission 1 for NDA 019943 with status AP dated 1995-03-30, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1993
Regulatory
Drugs@FDA application NDA020263↗
The official Drugs@FDA dataset lists original submission 1 for NDA 020263 with status AP dated 1993-04-16, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1990
Regulatory
Drugs@FDA application NDA020011↗
The official Drugs@FDA dataset lists original submission 1 for NDA 020011 with status AP dated 1990-10-22, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1989
Regulatory
Drugs@FDA application NDA019732↗
The official Drugs@FDA dataset lists original submission 1 for NDA 019732 with status AP dated 1989-01-26, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
1985
Regulatory
Drugs@FDA application NDA019010↗
The official Drugs@FDA dataset lists original submission 1 for NDA 019010 with status AP dated 1985-04-09, and names leuprolide acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026